8-K: Talphera Advances CRRT Study, Sees Guideline Boost

Talphera announced Q2 2026 results, highlighting 75% enrollment in its NEPHRO CRRT study and positive inclusion of nafamostat in draft KDIGO guidelines, alongside an increased market size estimate.

Summary

• Talphera, Inc. reported its second quarter 2026 financial results and provided a corporate update.
• The NEPHRO CRRT clinical study for nafamostat has reached 75% enrollment and is expected to be completed by year-end.
• Draft 2026 KDIGO guidelines now include nafamostat as an acceptable CRRT anticoagulant, a positive shift from previous guidelines.
• Updated market research estimates 200,000 annual U.S. CRRT procedures by 2027, a 21% increase from prior estimates.
• The company had $17.1 million in cash and investments as of June 30, 2026.
• Combined R&D and SG&A expenses were $3.9 million for Q2 2026, compared to $3.7 million in Q2 2025.
• Net loss for Q2 2026 was $4.3 million, or $0.06 per share, compared to a net loss of $3.5 million, or $0.10 per share, in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by progress in clinical trials and favorable guideline updates, despite continued net losses.

Positives

• NEPHRO CRRT study enrollment has reached 75%, on track for completion this year.
• Draft 2026 KDIGO guidelines cite nafamostat as an acceptable CRRT anticoagulant, a favorable change.
• Updated market research indicates a 21% increase in estimated annual U.S. CRRT procedures to 200,000 by 2027.
• Talphera regained Nasdaq compliance with the $1 bid price rule.
• The company has a cash and investments balance of $17.1 million as of June 30, 2026.

Negatives

• The company reported a net loss of $4.3 million for the second quarter of 2026.
• Net loss per share was $0.06 for Q2 2026, compared to $0.10 in Q2 2025.
• Combined R&D and SG&A expenses increased to $3.9 million in Q2 2026 from $3.7 million in Q2 2025.

Risks

• Clinical studies may not be fully enrolled or completed, or confirm any safety, efficacy, or other potential product characteristics.
• Developmental product candidates may not be beneficial to patients or healthcare providers or be successfully commercialized.
• Risks related to obtaining regulatory approvals for developmental product candidates.
• Risks related to the ability to implement development plans and commercial launch plans.
• Risks related to liquidity and maintaining sufficient capital resources to conduct clinical studies.

Future Outlook

The company expects the NEPHRO CRRT clinical study to be completed by the end of 2026. Updated market research suggests a significant increase in the U.S. CRRT procedures market. The inclusion of nafamostat in draft KDIGO guidelines is seen as a positive indicator for its future commercial opportunity.

Management Comments

• "Reaching 75% enrollment in the NEPHRO CRRT study keeps us on track for completion by year-end," stated Vince Angotti, CEO of Talphera.
• "Site realignment is complete, with all target clinical sites now activated. We are particularly pleased with the high level of engagement from our principal investigators and study site personnel."
• "In addition, the evolving treatment landscape continues to reinforce the potential role for nafamostat in CRRT. The KDIGO 2026 Clinical Practice Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) is currently pending final publication following the close of its public comment period in May. The guideline references nafamostat as an acceptable regional anticoagulant during CRRT. This is a positive change from KDIGOs last published AKI guidelines," continued Mr. Angotti.
• "Separately, our updated market research on CRRT treatment patterns indicates that approximately 200,000 CRRT procedures will be performed in 2027 in the U.S., an increase of 21% over our prior estimate. As we near completion of enrollment, we look forward to hosting an investor event to share these findings and discuss the commercial opportunity for nafamostat, if approved, including the potential favorable implications of the evolving KDIGO guidelines."

Industry Context

StockSavvy.ai notes that the inclusion of nafamostat in the draft KDIGO guidelines is a significant development, potentially validating its therapeutic approach in the critical care setting. The increased market size estimate for CRRT procedures also suggests a growing need for effective anticoagulation therapies in this segment.

Stakeholder Impact

• Shareholders: Positive outlook due to clinical trial progress and favorable guideline changes, potentially increasing future value, though continued net losses are a concern.
• Patients: Potential benefit from an approved nafamostat therapy for CRRT, offering an alternative anticoagulant.
• Healthcare Providers: May have new treatment options for CRRT patients, especially those who cannot tolerate heparin or are at bleeding risk.

Next Steps

• Complete the NEPHRO CRRT clinical study by year-end 2026.
• Host an investor event to share market research findings and discuss the commercial opportunity for nafamostat.
• Await final publication of the KDIGO 2026 Clinical Practice Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD).

Key Dates

Recommendation

The company shows promising clinical development and positive regulatory signals with the KDIGO guideline update, alongside an expanding market. However, continued net losses and the inherent risks of drug development warrant a cautious 'hold' until further clinical and commercial milestones are achieved.

Keywords

nafamostat, CRRT, anticoagulant, clinical study, KDIGO guidelines, acute kidney injury, pharmaceutical, renal replacement therapy